



IFW

Our Reference No. 10723-107

THE UNITED STATES PATENT AND TRADEMARK OFFICE

~~CONFIDENTIAL~~
In re Application of

Stuart A. Berger et al.

Serial No. 10/542,602

International Filing Date: January 19, 2004

International Appl. No.: PCT/CA2004/000033

For: **Pharmaceutical Compositions and Methods for Treating Multidrug Resistant Cancer**

Art Unit: Not yet assigned

Examiner: Not yet assigned

The Commissioner for Patents
The United States Patent and Trademark Office
P.O. Box 1450
Alexandria, VA
U.S.A. 22313-1450

Dear Sir:

FILING OF AN INFORMATION DISCLOSURE STATEMENT

In accordance with 37 CFR 1.97 and 1.98, and in recognition of the duty of disclosure set forth in 37 CFR 1.56, Applicants hereby submit an Information Disclosure Statement on Form PTO/SB/08a containing a listing of publications of which Applicants are aware.

All of the publications submitted herewith are in the English language. Accordingly a concise explanation of the relevance of the documents is not required.

The Examiner is requested to indicate consideration of these documents by initialling the appropriate column.

Applicants reserve the right to contest the applicability of any of these documents as prior art against the subject application. If the Examiner has any questions concerning this Information Disclosure Statement, he/she is requested to contact the undersigned.

Entry of the enclosed Information Disclosure Statement is believed to be in order and is respectfully requested.

This Information Disclosure Statement is being filed before the issuance of a first official action, and therefore no fees are required. However, please charge our deposit account No. 02-2095 if such a fee is required.

Respectfully submitted,

Stuart A. Berger et al.

A handwritten signature in cursive script, reading "Katina Loucaides", is written over a horizontal line.

Katina Loucaides
Registration No. 56,622

Dated: February 1, 2006

Bereskin & Parr
Box 401, 40 King Street West
Toronto, Ontario, Canada
M5H 3Y2

(416) 364-7311

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1041-A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet	1	of	2
-------	---	----	---

Complete if Known

Application Number	10/542,602 (PCT/CA2004/000033)
--------------------	--------------------------------

<i>I.A. Filing Date</i>	January 19, 2004
-------------------------	------------------

First Named Inventor	Stuart A. Berger
----------------------	------------------

Art Unit	Not yet assigned
----------	------------------

Examiner Name	Not yet assigned
----------------------	-------------------------

Attorney Docket Number	10723-107
------------------------	-----------

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS


[illegible]

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



PTO/SB/08b(08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449 (Rev. 10/01)

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 2 of 2

Complete if Known

Application Number	10/542,602 (PCT/CA2004/000033)
I.A. Filing Date	January 19, 2004
First Named Inventor	Stuart A. Berger
Art Unit	Not yet assigned
Examiner Name	Not yet assigned
Attorney Docket Number	10723-107

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	1	YICHENG ZHANG and STUART A. BERGER, Ketotifen reverses MDR1-mediated multidrug resistance in human breast cancer cells in vitro and alleviates cardiotoxicity induced by doxorubicin in vivo, <i>Cancer Chemother Pharmacol</i> 2003 51(5):407-414.	
	2	F. B. KLUGMAN et al., Effect of ketotifen on adriamycin toxicity: Role of histamine, <i>Cancer Letters</i> , 1998 39(2):145-152.	
	3	BRIASOULIS E. et al., Successful rechallenge with taxanes following prophylactic ketotifen in patients who had developed severe hypersensitivity reactions, <i>Annals of Oncology</i> 2000 11(7):899.	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.